Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3845097

Next Previous
Drug Profile

GSK 3845097

Alternative Names: GSK-3845097

Latest Information Update: 28 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Synovial sarcoma

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Synovial-sarcoma(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 05 Jan 2021 Phase-I clinical trials in Synovial sarcoma (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) before January 2021 (NCT04526509) (GlaxoSmithKline pipeline, January 2021)
  • 25 Aug 2020 GlaxoSmithKline plans a phase I trial in Synovial sarcoma (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Monotherapy) in USA (IV, Infusion) in September 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top